iOnctura announces expansion of roginolisib clinical trial program to NSCLC

iOnctura Netherlands United States of America Switzerland United Kingdom

Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in EuropeStudy will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapyView original content:https://www.prnewswire.co.uk/news-releases/ionctura-announces-expansion-of-roginolisib-clinical-trial-program-to-nsclc-302191025.html